	US 12,435,131 B2
	Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
Susan H. Tam, Garnet Valley, PA (US); Di Zhang, Hillsborough, NJ (US); Lihua Shi, Wynnewood, PA (US); and Man-Cheong Fung, Ringoes, NJ (US)
Assigned to Tavotek Biotherapeutics (Hong Kong) Limited, Hong Kong (CN)
Appl. No. 17/625,934
Filed by Tavotek Biotherapeutics (Hong Kong) Limited, Hong Kong (CN)
PCT Filed Jul. 10, 2020, PCT No. PCT/US2020/041642 § 371(c)(1), (2) Date Jan. 10, 2022, PCT Pub. No. WO2021/007533, PCT Pub. Date Jan. 14, 2021.
Claims priority of provisional application 62/873,051, filed on Jul. 11, 2019.
Prior Publication US 2022/0251186 A1, Aug. 11, 2022
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/244 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

40 Claims

1. An isolated antibody or an antigen-binding fragment thereof that specifically binds to thymic stromal lymphopoietin TSLP and neutralizes, inhibits, blocks, abrogates, reduces, or interferes with an activity of TSLP;

wherein the isolated antibody or an antigen-binding fragment thereof comprises complementarity determining region (CDR) sequences HCDR1, HCDR2, HCDR3 of the heavy chain as according to SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; and

wherein the isolated antibody or an antigen-binding fragment thereof comprises complementarity determining region (CDR) sequences LCDR1, LCDR2, LCDR3 of the light chain as according to SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.